Latigo Biotherapeutics
52 employees
Biotech/Pharma
Series B · $285.0M
Open positions (4)
Company details
Team Size52
IndustryBiotech/Pharma
Funding
Total raised
$285.0M
Last stage
Series B
Investors
Foresite Capital
Total raised
$285.0M
Last stage
Series B
Investors
Desmond Padhi
Amgen veteran who headed the pharma giant's pharmacokinetics team and various therapeutic divisions for 19 years; spearheaded Latigo's growth as Westlake operating partner and served as interim CEO at launch.
Nima Farzan
Brings more than two decades of leadership in biopharma; former CEO of Kinnate Biopharma (led $270M IPO and sale to Xoma); former President & CEO of PaxVax; holds MBA from Harvard Business School and BA in human biology from Stanford.
Sean Harper
Amgen veteran with 16 years at the company, culminating in leading R&D; co-founding managing director at Westlake Village BioPartners, which founded and incubated Latigo in 2020.
No applications, no recruiter spam. Just the intro.
A few questions to make sure this role is the right shape for you. Two minutes.
I write the intro, send it to the founder, and handle the back-and-forth.
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.